News

Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib.

In an interview with Targeted Oncology, Hatem Soliman, MD, provides an overview on testing for HER2-positive breast cancer and the available therapies in the first-, second-, and third-line settings.

Tanios S. Bekaii-Saab, MD, FACP, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study.

According to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.

Findings from the phase 3 PROpel have led to the FDA approval of olaparib in combination with abiraterone and prednisone or prednisolone for a prostate cancer subgroup.

For Bladder Cancer Awareness Month, Jahan Aghalar, MD, discussed the latest advancements in treating patients with bladder cancer along with which targets have helped to push the field forward.

Joshua K. Sabari, MD, explains how the shortage of drugs in the oncology space, including carboplatin and cisplatin, began.

Rupesh Kotecha, MD, discusses the key findings from an analysis centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

Joyce O’Shaughnessy, MD, highlights advances in breast cancer management which will be presented at an upcoming medical meeting.

In a phase 1/2 study, THE-630 is displaying preliminary anti-tumor activity and tolerable safety in patients with advanced gastrointestinal stromal tumors.

The biologics license application for lifileucel has been accepted by the FDA for patients with advanced melanoma based on positive data from the C-144-01 clinical trial.

The FDA has approved the flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Results from TRIDENT-1 are supporting a new drug application for repotrectinib, a potential treatment for ROS1-positive advanced non–small cell lung cancer.

Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.

A number of novel immunotherapies, such as PD-1 inhibitors and targeted drug therapies with BRAF and MEK inhibitors, have become available for managing advanced melanoma.

Thomas Flaig, MD, discusses recent updates seen in the bladder cancer space and how they have led to changes to the NCCN guidelines.

A comprehensive analysis of the phase 1 LEGEND-2 study shows a correlation between cytokine release syndrome and coagulation disorders inpatient with multiple myeloma treated with CAR T cells.

Today, we are in the heyday of biomarker discovery, utilization, and translation to clinical practice.

Robert L. Ferris, MD, PhD, discusses what should be done when a trial results in a negative finding.

Adam Brufsky, MD, PhD, FACP, discusses background and previous clinical data on palbociclib as a treatment option for patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.

A study looking at mortality rates from major cancer types may help inform cancer prevention and treatment strategies, and lead to a reduction to the global cancer disparities seen today.

With sitravatinib plus nivolumab, the primary end point of overall survival was not met in the phase 3 SAPPHIRE study in patients with advanced nonsquamous non-small cell lung cancer.

Tanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.

If granted approval, fruquintinib will be the first and only highly selective inhibitor of all 3 VEGF receptors to be approved in the United States for patients with metastatic colorectal cancer.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

In an interview with Targeted Oncology, Andreas Varkaris, MD, PhD, discussed findings from the ReDiscover trial and treating patients with PIK3CA mutations.

When used as a monotherapy or in combination with venetoclax, voruciclib was generally well tolerated and showed an encouraging preliminary efficacy signal in patients with acute myeloid leukemia or B-cell malignancies.

Retrospective research suggests that low skeletal muscle mass at baseline may negatively impact outcomes in patients receiving chimeric antigen receptor T-cell therapy.

Ropeginterferon alfa-2b-njft was added to the NCCN guidelines and granted category 2A status for the treatment of polycythemia vera.

No progression-free survival advantage was shown with milademetan compared with trabectedin in the phase 3 MANTRA study.